DNAnexus, a US-based provider of biomedical data analysis software, raised $200m in funding from investors including GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, yesterday.
Alternative investment firm Blackstone’s Growth fund led the round, which also featured Perceptive Advisors, Innovatus Capital Partners, Foresite Capital and Northpond Ventures.
Founded in 2009, DNAnexus operates a cloud-based platform enabling clinical researchers to stores, share, analyse and manage complex clinical data. It claims the platform contains 65 petabytes of data has more than 12,000 users across 48 countries.
The company last raised money in mid-2020 when it hauled in $100m from investors including GV and biotech company Regeneron Pharmaceuticals to take its total funding to $273m. GV also invested in a $68m round in 2019 that included WuXi NextCode, the genome technology subsidiary of pharmaceutical firm WuXi AppTec.
GV had first participated in the company’s $15m series B round in 2011 alongside TPG Biotech, First Round Capital, K9 Ventures, SoftTech VC and Felicis Ventures. It returned for a $15m series C round in 2014, while WuXi AppTec invested $15m the following year.
WuXi Nextcode, GV and software provider Microsoft all contributed to a $58m round in 2018 that was led by Foresite Capital and which also featured TPG Biotech, Claremont Creek Ventures and MidCap Financial,
DNAnexus chief executive Richard Daly said: “The funding enables us to accelerate our product roadmap to meet the global demand for technologies harnessing the power of biomedical data and driving precision medicine forward.”
